EMERGING EVIDENCE THAT MAKES A BIG DIFFERENCE

ADA, 2022

American Diabetes Association

ADA, 2022: American Diabetes Association considers aspirin as a primary prevention strategy

For diabetic patients who are at increased cardiovascular risk:

Aspirin therapy (75–162 mg/day) may be considered as a primary prevention strategy, after a comprehensive discussion with the patient on the benefits versus the comparable increased risk of bleeding.1

Aspirin has been shown to be effective in reducing cardiovascular morbidity and mortality in high-risk patients with previous MI or stroke (secondary prevention) and is strongly recommended.1

For diabetic population with a history of atherosclerotic cardiovascular disease.

Use aspirin therapy (75– 162 mg/day) as a secondary prevention strategy (single antiplatelet therapy).1

Combination of low-dose aspirin and P2Y12 inhibitor for a year or more after an acute coronary syndrome (Dual antiplatelet therapy).1

Long-term dual antiplatelet treatment should be considered for patients with prior coronary intervention, high ischemic risk, and low bleeding risk.1

MI: myocardial infarction; P2Y12: platelet adenosine diphosphate P2Y12 receptor.

Reference

  1. Boris D, Vanita R A, George B et al.10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022. Diabetes Care. 2021;45(Supplement_1):S144-S174.